BioSpace News Archive

Corbus Pharmaceuticals, a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has appointed Mr. Paris Panayiotopoulos to its Board of Directors.

Sensorion announces its results for the first half of the year ending June 30, 2017, as well as its recent developments.

Synthego, a leading provider of genome engineering solutions, announces an investment from Intel Capital for the advancement of bioinformatics tools and technologies. This represents Intel Capital’s first financing in bioinformatics related to the CRISPR workflow.

Natasha Leporé, PhD, a principal investigator in the Department of Radiology and Imaging at Children’s Hospital Los Angeles, has been awarded $1.7 million from the National Institute of Biomedical Imaging and Bioengineering of the NIH.

GenMark Diagnostics today announced that it plans to release its third quarter earnings results after market close on Thursday, November 2, 2017.

Alkermes plc will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Oct. 26, 2017, to discuss the company’s third quarter 2017 financial results.

[19-October-2017] TORONTO, Oct. 19, 2017 /PRNewswire/ - SQI Diagnostics Inc. (“SQI Diagnostics” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective October 16, 2017, it granted 350,000 stock options to the Company’s

QIAGEN today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic screening and genetic counseling company.

Titan Pharma announced today the planned presentation of non-clinical data on the use of its ProNeura subdermal implant for the long-term, sustained delivery of liothyronine (L-T3) during a poster session on Oct. 20 at the 87th annual conference of the American Thyroid Association in Victoria, British Columbia, Canada.

The drug hydroxyurea does not appear to increase the risk of malaria infection in patients with sickle cell anemia who live in malaria-endemic regions, according to a study published online today in Blood, the Journal of the American Society of Hematology (ASH).